Researchers at Memorial Sloan Kettering Cancer Center discovered that nearly all cells in the prostate gland contribute to its regrowth after androgen-deprivation therapy. Luminal cells acquire stem-like properties without hormone influence, leading to implications for prostate cancer treatment and potential therapeutic strategies.
Researchers have found a promising candidate to advance pancreatic cancer immunotherapy: innate lymphoid cells (ILCs), particularly ILC2s. Activating ILC2s with interleukin 33 (IL-33) enhances antitumor activity, which may complement existing checkpoint inhibitors.
Cancer cells can change their developmental identity, enabling them to spread and evade the immune system. Researchers identified specific cell types involved in lung development that are also present in cancer metastases.
Researchers at Memorial Sloan Kettering Cancer Center have developed more potent CAR T cells using CRISPR/Cas9 genome editing, which can kill tumor cells longer and resist exhaustion. This breakthrough could lead to safer and more effective use of immunotherapy in cancer patients.
A clinical trial found that patients with tumors overexpressing DLL3 responded better to the experimental drug rovalpituzumab tesirine (Rova-T), achieving stabilization of disease and significant tumor reductions. The results suggest Rova-T may be a promising treatment option for advanced small cell lung cancer.
Liquid biopsies may help predict treatment responses and genetic mutations that impact prognosis in advanced breast cancer. The tests analyzed tumor DNA in blood samples, revealing potential benefits and risks of combining therapies.
A recent study published in JAMA Oncology examined cancer-care outcomes among US hospitals and found significant differences in long-term survival rates among four major categories of hospitals: PPS-exempt, NCI cancer centers, AMC, and other hospitals. The analysis revealed substantial gaps in survival rates, with patients treated at P...
Researchers from MSK Cancer Center announce results from the first published basket study, a clinical trial design that explores drug responses based on specific tumor mutations. The study found preliminary clinical efficacy of vemurafenib in multiple non-melanoma BRAFV600-mutated cancers.
Researchers found that combining immunotherapy drugs nivolumab and ipilimumab significantly increases progression-free survival in advanced melanoma patients, with a median PFS of 11.5 months compared to 6.9 months for nivolumab alone.
In an early-phase clinical trial, a new type of cancer therapy targeting the IDH2 gene produced dramatic results in patients with advanced leukemia. The study found that AG-221 blocked the mutated protein, allowing immature white blood cells to develop normally and leading to complete or partial remissions.
Studies presented at the ASH Annual Meeting show that immunotherapy drugs pembrolizumab and nivolumab are producing dramatic responses in Classical Hodgkin lymphoma patients. These results are promising for patients with few treatment options left, highlighting the potential of immunotherapies to work in various types of cancer.
A late-stage clinical trial demonstrated that brentuximab vedotin can improve progression-free survival and overall survival in patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplant. The study showed a 20% improvement in progression-free survival rate and high response rates among patients.
Researchers at Memorial Sloan Kettering Cancer Center have made a breakthrough discovery that may lead to a reliable diagnostic test for predicting which patients will respond to immunotherapy drugs like ipilimumab. The study found that tumors with high numbers of gene mutations are more likely to benefit from the treatment.
Researchers at Memorial Sloan Kettering Cancer Center have successfully grown prostate cancer organoids from human tumors, providing a new tool for testing cancer drugs and personalizing treatment. The addition of these organoids doubles the number of existing prostate cancer cell lines, offering a more accurate representation of the d...
A review of over 240 patient cases found transplants to be highly effective in treating severe combined immunodeficiency (SCID) in young children. Early transplantation without infection results in exceptionally good outcomes, with overall five-year survival rates ranging from 77-93%.
A study by Memorial Sloan Kettering Cancer Center found that genomic tumor testing can improve survival for patients with advanced lung cancers. The test identified oncogenic drivers in 64% of tumors, leading to improved outcomes when matched with targeted therapies.
Researchers found that PLX3397, a tyrosine kinase inhibitor, induced partial responses and stable disease in 79% of evaluable patients with advanced PVNS. The drug demonstrated significant tumor size reduction and minimal side effects.
Researchers discovered that cancer cells hug capillaries and express specific proteins to survive in the brain. The tumor cells produce a protein acting like Velcro to attach themselves to blood vessels, allowing them to grow into new tumors.
Researchers at Memorial Sloan Kettering Cancer Center reported remarkable results from a clinical study using genetically modified T cells to treat advanced leukemia. The treatment achieved a 88% complete remission rate, exceeding the response rate of salvage chemotherapy alone.
Researchers at Memorial Sloan-Kettering Cancer Center developed a new approach for cancer therapy development using tumor genomic signatures. The study confirms two major hypotheses, showing that a limited number of genetic events cause most tumor subtypes and that oncogenic signatures are largely independent of tissue origin.
A team of researchers has discovered a genetic mutation specific to risk of childhood leukemia, providing a potential window into inherited causes. The PAX5 gene mutation was found in several family members with childhood acute lymphoblastic leukemia (ALL), increasing the risk of developing the disease.
A new study from Memorial Sloan Kettering Cancer Center found that MRI use in women with early breast cancer did not reduce local recurrence or contralateral breast cancer rates. The study, which looked at over 2,300 patients, suggests that the benefits of MRI may be limited to other patient groups.
Researchers found that a specific pattern in tumor pathology is strongly associated with cancer recurrence. Patients with this pattern are more likely to benefit from lobectomy and have a 75% lower risk of recurrence. The study may lead to new technology to precisely identify tumors with this pattern before surgery.
Researchers have developed a new method for identifying cell of origin of proteins in multicellular environments, enabling comprehensive mapping of cell-cell communication. This technique, CTAP, exploits amino acid biosynthesis and stable isotope labeling to link proteins directly to specific cell types.
Researchers found that combining ipilimumab and nivolumab led to long-lasting tumor shrinkage in over half of patients with metastatic melanoma. The combination resulted in a 50% tumor size reduction in 40% of patients, with some experiencing shrinkages of over 80% within 12 weeks.
Researchers found that the experimental drug selumetinib significantly improved progression-free survival, with nearly 16 weeks of PFS, and showed significant tumor shrinkage in patients with advanced uveal melanoma. This breakthrough offers a new treatment option for a historically untreatable disease.
A large-scale genomic analysis identified distinct subtypes of endometrial cancer based on their genomic makeup, which may respond to targeted drugs already being tested in clinical trials. The findings suggest that a significant portion of high-grade endometrioid tumors should be treated more aggressively after surgery.
A new human monoclonal antibody, ESK1, has been developed to target proteins associated with many types of cancer, including leukemia and breast cancer. The antibody recognizes a protein called WT1, which is overexpressed in these cancers, and can kill cancer cells in preclinical research.
Researchers found that selumetinib increased iodine uptake in tumors resistant to radioiodine therapy, allowing some patients to undergo treatment. The study shows promise for RAS-mutant disease and paves the way for a larger clinical trial.
Researchers have developed a new technique to create targeted immunotherapies for cancer, recognizing antigens on cancer cells that are not found on healthy cells. The approach uses chimeric antigen receptors (CARs) and costimulatory receptors (CCRs), allowing T cells to attack specific types of cancer cells while sparing normal cells.
A study found that women treated with chest radiation for childhood cancer have a high risk of developing breast cancer comparable to those with BRCA1/2 mutations. The study analyzed data from over 1,200 female survivors and found a 24% breast cancer incidence by age 50.
Researchers at Memorial Sloan Kettering Cancer Center have identified three genetic targets in approximately 50% of patients with squamous cell carcinomas. This breakthrough enables personalized treatment for a previously untreatable type of lung cancer.
Researchers at Memorial Sloan-Kettering Cancer Center have discovered an antibody therapy that prevents lethal gastrointestinal damage following radiation exposure in mice. The treatment, which targets ceramide molecules, improved survival rates from 0% to 80% among mice exposed to high levels of ionizing radiation.
Researchers have identified genetic abnormalities that help doctors predict patient prognoses and guide treatment decisions for AML. The study shows that nearly two-thirds of patients can be categorized into clear prognostic groups, leading to improved treatment outcomes.
Researchers report a rare phenomenon where localized radiation therapy leads to disappearance of metastatic tumors, suggesting an immune system-activating effect. The combination of ipilimumab and radiation may offer a promising approach for treating advanced melanoma.
A study published in The New England Journal of Medicine found that removing polyps by colonoscopy prevents not only colorectal cancer development but also deaths from the disease. Patients who underwent the procedure had a 53% lower death rate from colorectal cancer compared to those without removed polyps.
Researchers found that PSA velocity is a poor predictor of prostate cancer and may lead to unnecessary biopsies. The study, which analyzed data from over 5,000 men, suggests that using changes in PSA levels as a basis for recommending biopsy can result in many unnecessary procedures.
Researchers at Memorial Sloan-Kettering Cancer Center have developed a novel ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer. The first-in-human clinical trial aims to evaluate the distribution, tissue uptake, and safety of the particles in humans using PET imaging.
Researchers have identified a novel oncogene GNA11 associated with uveal melanoma in over 40% of tumor samples. This discovery offers new targets and treatments for the disease, which affects about 1,500 people in the US each year.
A recent study published in PLoS Genetics has identified genetic variants that may modify the risk of breast cancer in women with BRCA2 mutations. The research found that variants near the ZNF365 gene decreased breast cancer risk by approximately 25 percent, while other variants like FGFR2 increased risk.
A study at Memorial Sloan-Kettering Cancer Center found that introducing colon cancer screening during routine mammography screening increased minority access to preventive care. The research introduced colon cancer screening to women living in Harlem, resulting in similar colonoscopy findings as the general population.
A team of researchers has discovered genetic changes in glioblastoma, a common type of primary brain cancer, that contribute to its aggressiveness. The study found that tumors with rearrangements in receptor genes are more common than previously thought, suggesting new targets for therapies.
A new targeted therapy called PLX4032 has been linked to an 80% response rate in treating advanced melanoma. The treatment, which targets the BRAF protein, has shown significant tumor shrinkage and improved quality of life for some patients.
A new prediction tool calculates individualized risk for local recurrence five and ten years after surgery, helping physicians and patients weigh treatment options. The nomogram integrates available information to estimate absolute risk, providing a valuable tool in decision-making.
A comprehensive genomic analysis of prostate cancer has identified key alterations in the androgen receptor pathway and defined subsets of low- and high-risk disease. The study provides valuable resources for cancer research and may lead to the creation of a genetic-based test to determine which tumors require aggressive treatment.
A new multicenter study has found that MDV3100 is safe and effective for patients with castration-resistant prostate cancer. The drug slowed tumor growth, reduced PSA levels, and stabilized disease progression, offering new hope for patients with limited treatment options.
Clinicians often miss vital symptoms and underestimate their severity in clinical trials, leading to under-reporting of adverse events. Patient self-reporting can enhance symptom and event data quality and give patients a voice in healthcare decision-making.
The Dartmouth Atlas hospital ratings are being used by policy makers despite their limitations, which fail to account for differences in patient types and outcomes. This could lead hospitals to prioritize conforming to the rating system over improving care quality.
A new study reveals that self-seeding allows circulating tumor cells to return to their primary tumor and promote local growth while increasing potential for distant metastases. The research identifies key genes responsible for this process, which may lead to targeted therapies to slow or prevent tumor progression.
A new study from Memorial Sloan Kettering Cancer Center found that clinicians' and patients' reports of treatment side effects differ significantly, but together provide a more complete picture. Patients generally reported adverse symptoms earlier, more frequently, and with greater severity than their clinicians.